172 related articles for article (PubMed ID: 37633414)
1. Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study.
Rampotas A; Sockel K; Panitsas F; Theuser C; Bornhauser M; Hernani R; Hernandez-Boluda JC; Esquirol A; Avenoso D; Tsirigotis P; Robin M; Czerw T; Helbig G; Roddie C; Lambert J; McLornan DP
Transplant Cell Ther; 2023 Nov; 29(11):687.e1-687.e7. PubMed ID: 37633414
[TBL] [Abstract][Full Text] [Related]
2. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
[TBL] [Abstract][Full Text] [Related]
3. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD.
He F; Warlick E; Miller JS; MacMillan M; Verneris MR; Cao Q; Weisdorf D
Bone Marrow Transplant; 2016 Aug; 51(8):1107-12. PubMed ID: 27064686
[TBL] [Abstract][Full Text] [Related]
4. Donor Lymphocyte Infusion for Relapsed Acute Leukemia or Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation: A Single-Institute Retrospective Analysis.
Ogasawara M; Nozu R; Miki K; Sugimura S; Kojima K; Hidaka D; Ogasawara R; Okada K; Sugita J; Kobayashi N; Imamura M; Ota S
Intern Med; 2024 Jan; 63(2):197-205. PubMed ID: 37225485
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
6. Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party.
Santoro N; Mooyaart JE; Devillier R; Koc Y; Vydra J; Castagna L; Gülbas Z; Martin JD; Araujo MC; Kulagin A; Arat M; Arroyo CH; Martelli MP; Di Ianni M; Hoogenboom JD; de Wreede LC; Ruggeri A; Chabannon C
Bone Marrow Transplant; 2023 Jan; 58(1):54-60. PubMed ID: 36216975
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients.
Al-Shaibani E; Bautista R; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Gerbitz A; Pasic I; Mattsson J; Michelis FV
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e327-e334. PubMed ID: 34866020
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
Yang L; Lai X; Yang T; Lu Y; Liu L; Shi J; Zhao Y; Wu Y; Chen Y; Yu J; Xiao H; Ouyang G; Ren J; Cao J; Hu Y; Tan Y; Ye Y; Cai Z; Xu W; Huang H; Luo Y
Bone Marrow Transplant; 2024 Jan; 59(1):85-92. PubMed ID: 37907756
[TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
10. Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.
Bar M; Flowers MED; Storer BE; Chauncey TR; Pulsipher MA; Thakar MS; Bethge W; Storb R; Maloney DG; Sandmaier BM
Biol Blood Marrow Transplant; 2018 Feb; 24(2):308-313. PubMed ID: 29032276
[TBL] [Abstract][Full Text] [Related]
11. Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter.
Ros-Soto J; Snowden JA; Szydlo R; Nicholson E; Madrigal A; Easdale S; Potter M; Ethell M; Anthias C
Transplant Cell Ther; 2022 Apr; 28(4):183.e1-183.e8. PubMed ID: 35104660
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Sheth AH; Vetsa S; Grimshaw A; Giri S; Podoltsev NA; Gowda L; Tamari R; Tallman MS; Rampal RK; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Oct; 27(10):873.e1-873.e13. PubMed ID: 34052505
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
Bethge WA; Hegenbart U; Stuart MJ; Storer BE; Maris MB; Flowers ME; Maloney DG; Chauncey T; Bruno B; Agura E; Forman SJ; Blume KG; Niederwieser D; Storb R; Sandmaier BM
Blood; 2004 Feb; 103(3):790-5. PubMed ID: 14525766
[TBL] [Abstract][Full Text] [Related]
14. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743
[TBL] [Abstract][Full Text] [Related]
15. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
[TBL] [Abstract][Full Text] [Related]
16. A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT.
Lu N; Lin J; Wang LL; Li YY; Wang LJ; Gao CJ; Liu DH; Gao XN
Int J Hematol; 2022 May; 115(5):713-727. PubMed ID: 35128587
[TBL] [Abstract][Full Text] [Related]
17. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
[TBL] [Abstract][Full Text] [Related]
18. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
[No Abstract] [Full Text] [Related]
19. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
Guillaume T; Thépot S; Peterlin P; Ceballos P; Bourgeois AL; Garnier A; Orvain C; Giltat A; François S; Bris YL; Fronteau C; Planche L; Chevallier P
Transplant Cell Ther; 2021 Oct; 27(10):839.e1-839.e6. PubMed ID: 34224913
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
